Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AKAMPION

< Previous 1 2 3 Next >
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
From AKAMPION
Via GlobeNewswire
BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction
From AKAMPION
Via GlobeNewswire
Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment
From AKAMPION
Via GlobeNewswire
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
From AKAMPION
Via GlobeNewswire
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
From AKAMPION
Via GlobeNewswire
Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
From AKAMPION
Via GlobeNewswire
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
From AKAMPION
Via GlobeNewswire
Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
From AKAMPION
Via GlobeNewswire
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
From AKAMPION
Via GlobeNewswire
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
From AKAMPION
Via GlobeNewswire
EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases
From AKAMPION
Via GlobeNewswire
InfanDx AG Revises Strategy and Broadens Diagnostics Pipeline for Child Health
From AKAMPION
Via GlobeNewswire
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
From AKAMPION
Via GlobeNewswire
HpVac reports positive effects of its lead compound HpVac-R13 in a murine model of allergic asthma following oral administration
From AKAMPION
Via GlobeNewswire
Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
From AKAMPION
Via GlobeNewswire
Cellbox Solutions Raises EUR 6.5 Million in Series A1 Financing Round
From AKAMPION
Via GlobeNewswire
Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants
From AKAMPION
Via GlobeNewswire
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
From AKAMPION
Via GlobeNewswire
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
From AKAMPION
Via GlobeNewswire
Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
From AKAMPION
Via GlobeNewswire
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
From AKAMPION
Via GlobeNewswire
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
From AKAMPION
Via GlobeNewswire
HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer
From AKAMPION
Via GlobeNewswire
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
From AKAMPION
Via GlobeNewswire
Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
From AKAMPION
Via GlobeNewswire
HpVac Announces New Animal Data of its Lead Compound Demonstrating Protection Against Allergic Asthma
From AKAMPION
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.